Explore / Peer-reviewed article
Peer-reviewed articleOpen access

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey.

Plourde LiD, Chang SL, Farzin H, Gagnon PiD, Hébert J, Foxman R, Deschamps P, Provost F, Masse-Grenier M, Stephan JFiD, Cheung K, Joly Y, Fallu JSiD, Dorval MiD

Palliative medicineJan 22, 2024License: open accessCanada, United States16 citationsDOI: 10.1177/02692163231222430

Abstract

<h4>Background</h4>Internationally, there is a growing interest in the potential benefits of psilocybin-assisted therapy to treat existential distress at the end of life. However, the social acceptability of this therapy is not yet well known.<h4>Aim</h4>This study assesses the social acceptability of the medical use of psilocybin to treat existential distress at the end of life.<h4>Design</h4>An online survey was conducted in Canada between November 23 and December 4, 2022. The questionnaire included items pertaining to perceptions, attitudes and concerns towards psilocybin-assisted therapy to treat existential distress at the end of life.<h4>Participants</h4>The sample (<i>n</i> = 2800) was stratified by province, age and sex. Participants were adults from four provinces of Canada: Québec, Ontario, Alberta and British Columbia.<h4>Results</h4>Overall, 79.3% considered psilocybin-assisted therapy a reasonable medical choice for a patient suffering from existential distress at the end of life, 84.8% agreed that the public health system should cover the costs of the intervention and 63.3% would welcome the legalisation of psilocybin for medical purposes. Previous psilocybin use (<i>p</i> < 0.0001, for all dependent variables), exposure to palliative care (<i>p</i> < 0.05, for all dependent variables) and a progressive political orientation (<i>p</i> < 0.05, for all dependent variables) were associated with more favourable attitudes towards psilocybin-assisted therapy at the end of life.<h4>Conclusion</h4>The social acceptability of psilocybin-assisted therapy for existential distress at the end of life is rather high in Canada. These findings may contribute to efforts to mobilise resources and improve access to this emerging therapy in palliative and end of life care settings.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinPalliative care

Keywords

SurveyPublic OpinionEnd-of-lifePsychological DistressPsychedelic

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.